173 related articles for article (PubMed ID: 38069717)
1. The Role of Transporters in Future Chemotherapy.
Huttunen J; Huttunen KM
Chimia (Aarau); 2022 May; 76(5):454-459. PubMed ID: 38069717
[TBL] [Abstract][Full Text] [Related]
2. Amino acid derivative of probenecid potentiates apoptosis-inducing effects of vinblastine by increasing oxidative stress in a cancer cell-specific manner.
Huttunen J; Tampio J; Järvinen J; Montaser AB; Markowicz-Piasecka M; Huttunen KM
Chem Biol Interact; 2024 Jan; 388():110833. PubMed ID: 38101600
[TBL] [Abstract][Full Text] [Related]
3. Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents.
Huttunen J; Gynther M; Huttunen KM
Int J Pharm; 2018 Oct; 550(1-2):278-289. PubMed ID: 30149128
[TBL] [Abstract][Full Text] [Related]
4. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.
Hushmandi K; Einollahi B; Saadat SH; Lee EHC; Farani MR; Okina E; Huh YS; Nabavi N; Salimimoghadam S; Kumar AP
Mol Metab; 2024 Jun; 84():101952. PubMed ID: 38705513
[TBL] [Abstract][Full Text] [Related]
5. Refinement of safety and efficacy of anti-cancer chemotherapeutics by tailoring their site-specific intracellular bioavailability through transporter modulation.
Dhakne P; Pillai M; Mishra S; Chatterjee B; Tekade RK; Sengupta P
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188906. PubMed ID: 37172652
[TBL] [Abstract][Full Text] [Related]
6. L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells.
Montaser A; Markowicz-Piasecka M; Sikora J; Jalkanen A; Huttunen KM
Int J Pharm; 2020 Aug; 586():119585. PubMed ID: 32599132
[TBL] [Abstract][Full Text] [Related]
7. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
8. Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers.
Bharadwaj R; Jaiswal S; Velarde de la Cruz EE; Thakare RP
Diseases; 2024 Mar; 12(3):. PubMed ID: 38534987
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel microscale thermophoresis ligand-binding assay for characterization of SLC solute carriers using oligopeptide transporter PepT1 (SLC15 family) as a model system.
Clémençon B; Lüscher BP; Hediger MA
J Pharmacol Toxicol Methods; 2018; 92():67-76. PubMed ID: 29580877
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
11. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.
Wu CP; Calcagno AM; Ambudkar SV
Curr Mol Pharmacol; 2008 Jun; 1(2):93-105. PubMed ID: 19079736
[TBL] [Abstract][Full Text] [Related]
12. Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption.
Al-Ali AAA; Nielsen RB; Steffansen B; Holm R; Nielsen CU
Int J Pharm; 2019 Jul; 566():410-433. PubMed ID: 31125713
[TBL] [Abstract][Full Text] [Related]
13. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
15.
César-Razquin A; Girardi E; Yang M; Brehme M; Saez-Rodriguez J; Superti-Furga G
Front Pharmacol; 2018; 9():1011. PubMed ID: 30245630
[TBL] [Abstract][Full Text] [Related]
16. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.
Joyce H; McCann A; Clynes M; Larkin A
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):795-809. PubMed ID: 25836015
[TBL] [Abstract][Full Text] [Related]
17. Fetal membranes exhibit similar nutrient transporter expression profiles to the placenta.
Lintao RCV; Kammala AK; Vora N; Yaklic JL; Menon R
Placenta; 2023 Apr; 135():33-42. PubMed ID: 36913807
[TBL] [Abstract][Full Text] [Related]
18. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level.
Veiga-Matos J; Remião F; Motales A
J Pharm Pharm Sci; 2020; 23():333-356. PubMed ID: 32997956
[TBL] [Abstract][Full Text] [Related]
20. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
